-
RegMed XB is a translational product development platform that brings together Dutch and Flemish public and private stakeholders to accelerate the development of innovative regenerative therapies.
Infrastructure: RegMed XB's Pilot Factory
A seamless pathway for innovators to accelerate, de-risk, and scale regenerative therapies
read more
-
Two new Supervisory Board members
We are pleased to announce that, as of November 1st, 2024, our Supervisory Board will be strengthened by two new members: Floris Italianer and Arno van Son.
read more
RegMed XB and Nakanoshima Qross signed a memorandum of understanding
Last week, RegMed XB and Nakanoshima Qross (International Hub for Future Medicine) in Osaka, Japan, signed a memorandum of understanding to promote cooperation in the field of regenerative medicine.
read more
Three National Growth Fund-initiatives sign collaboration agreement
The consortia are joining forces to accelerate research, development and innovation in the area of ATMP’s and biopharmaceuticals.
read more -
Moonshots (research excellence)
-
Pilot Factory (infrastructure)
The RegMed XB Pilot Factory is one of the largest international infrastructures for regenerative medicine. It brings together all the expertise and infrastructure needed to bring regenerative medicine to the market.
-
RegMed XB's Ecosystem
Health Foundations
The following Dutch health foundations are involved in defining research objectives and provide guidance in the research we conduct to ensure we maintain focus on the patient.
read moreAcademic Partners
RegMed XB works together with (inter)national top-rated academic institutions and collaborates specifically and exclusively with researchers who contribute specific expertise to the Moonshot initiatives.
read moreIndustrial Partners
Partnering with companies offers access to their expertise in designing scalable and feasible products. Currently, we have strong partnerships with the following entities.
read moreGovernmental Partners
RegMed XB receives support from national and local governments to de-risk promising concepts from academia to proof of concept or initial clinical trial stages.
read more -
-
-
-
-
-
-
